Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Immunol ; 24(1): 34, 2023 09 26.
Artigo em Inglês | MEDLINE | ID: mdl-37752417

RESUMO

BACKGROUND: Rapid and accurate diagnosis of individuals with SARS-CoV-2 infection is an effective way to prevent and control the spread of COVID-19. Although the detection of SARS-CoV-2 viral RNA by RT-qPCR is the gold standard for COVID-19 testing, the use of antigen-detecting rapid diagnostic tests (Ag-RDTs) is emerging as a complementary surveillance tool as Omicron case numbers skyrocket worldwide. However, the results from Ag-RDTs are less accurate in individuals with low viral loads. RESULTS: To develop a highly sensitive and accurate Ag-RDT, 90 monoclonal antibodies were raised from guinea pigs immunized with SARS CoV-2 nucleocapsid protein (CoV-2-NP). By applying a capture antibody recognizing the structural epitope of the N-terminal domain of CoV-2-NP and a detection antibody recognizing the C-terminal tail of CoV-2-NP to an automated chemiluminescence flow-through membrane immunoassay device, we developed a novel Ag-RDT, CoV-2-POCube. The CoV-2-POCube exclusively recognizes CoV-2-NP variants but not the nucleocapsid proteins of other human coronaviruses. The CoV-2-POCube achieved a limit of detection sensitivity of 0.20 ~ 0.66 pg/mL of CoV-2-NPs, demonstrating more than 100 times greater sensitivity than commercially available SARS-CoV-2 Ag-RDTs. CONCLUSIONS: CoV-2-POCube has high analytical sensitivity and can detect SARS-CoV-2 variants in 15 min without observing the high-dose hook effect, thus meeting the need for early SARS-CoV-2 diagnosis with lower viral load. CoV-2-POCube is a promising alternative to currently available diagnostic devices for faster clinical decision making in individuals with suspected COVID-19 in resource-limited settings.


Assuntos
Anticorpos Monoclonais , COVID-19 , Humanos , Animais , Cobaias , SARS-CoV-2 , Teste para COVID-19 , COVID-19/diagnóstico , Sensibilidade e Especificidade , Imunoensaio
2.
J Biosci Bioeng ; 107(5): 535-7, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19393554

RESUMO

For substantial cell growth and exopolysaccharide (EPS) production of Bifidobacterium longum JBL05, anaerobic conditions (dissolved oxygen concentrations below 0.05 ppm) and the supplement of CO2 (> or = 20%) were required. Under these conditions, B. longum JBL05 produced EPS amounts of up to 2.9 g/l.


Assuntos
Bifidobacterium/crescimento & desenvolvimento , Bifidobacterium/metabolismo , Reatores Biológicos/microbiologia , Dióxido de Carbono/administração & dosagem , Polissacarídeos Bacterianos/metabolismo , Anaerobiose , Proliferação de Células/efeitos dos fármacos , Relação Dose-Resposta a Droga , Polissacarídeos Bacterianos/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...